Ovid Therapeutics (OVID) Revenue & Revenue Breakdown
Ovid Therapeutics Revenue Highlights
Latest Revenue (Y)
$391.69M
Latest Revenue (Q)
$169.00K
Main Segment (Y)
License
Ovid Therapeutics Revenue by Period
Ovid Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $391.69M | 25965.25% |
| 2022-12-31 | $1.50M | -99.28% |
| 2021-12-31 | $208.38M | 1551.57% |
| 2020-12-31 | $12.62M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Ovid Therapeutics generated $391.69M in revenue during NA 2023, up 25965.25% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Ovid Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $169.00K | 14.19% |
| 2024-03-31 | $148.00K | 4.55% |
| 2023-12-31 | $141.56K | 29.91% |
| 2023-09-30 | $108.97K | 45.30% |
| 2023-06-30 | $75.00K | 13.36% |
| 2023-03-31 | $66.16K | 42.96% |
| 2022-12-31 | $46.28K | 316.86% |
| 2022-09-30 | $11.10K | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $1.45M | -100.35% |
| 2021-12-31 | $-416.35M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $208.38M | 3553.80% |
| 2020-12-31 | $5.70M | -17.51% |
| 2020-09-30 | $6.91M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
Ovid Therapeutics generated $169.00K in revenue during Q2 2024, up 14.19% compared to the previous quarter, and up 255.44% compared to the same period a year ago.
Ovid Therapeutics Revenue Breakdown
Ovid Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 |
|---|---|---|
| Related Party | - | $196.00M |
| License | $1.50M | $12.38M |
Ovid Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 22: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 22 | Mar 22 | Mar 21 |
|---|---|---|---|
| Related Party | - | - | $196.00M |
| License | $11.10K | $1.45M | $12.38M |
Ovid Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: License (100.00%).
Ovid Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 22 | Mar 22 | Mar 21 |
|---|---|---|---|
| License | $11.10K | $1.45M | $12.38M |
| Related Party | - | - | $196.00M |
Ovid Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 22: License (100.00%).
Ovid Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OVID | Ovid Therapeutics | $391.69M | $169.00K |
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| CNTB | Connect Biopharma | - | - |
| NXTC | NextCure | - | - |
| TIL | Instil Bio | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
OVID Revenue FAQ
What is Ovid Therapeutics’s yearly revenue?
Ovid Therapeutics's yearly revenue for 2023 was $391.7M, representing an increase of 25965.25% compared to 2022. The company's yearly revenue for 2022 was $1.5M, representing a decrease of -99.28% compared to 2021. OVID's yearly revenue for 2021 was $208.38M, representing an increase of 1551.57% compared to 2020.
What is Ovid Therapeutics’s quarterly revenue?
Ovid Therapeutics's quarterly revenue for Q2 2024 was $169K, a 14.19% increase from the previous quarter (Q1 2024), and a 125.33% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $148K, a 4.55% increase from the previous quarter (Q4 2023), and a 123.70% increase year-over-year (Q1 2023). OVID's quarterly revenue for Q4 2023 was $141.56K, a 29.91% increase from the previous quarter (Q3 2023), and a 205.88% increase year-over-year (Q4 2022).
What is Ovid Therapeutics’s revenue growth rate?
Ovid Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 87.97%, and for the last 5 years (2019-2023) was 0%.
What are Ovid Therapeutics’s revenue streams?
Ovid Therapeutics's revenue streams in c 22 are License
What is Ovid Therapeutics’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Ovid Therapeutics was License. This segment made a revenue of $1.5M, representing 100.00% of the company's total revenue.